Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-12-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2019年第四次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures, attendance, and validity of resolutions passed at the 2019 fourth extraordinary general meeting of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement but a legal opinion on the meeting's compliance and validity. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal opinion related to a shareholder meeting without being a direct announcement of voting results or a management/board change notice.
2019-12-08 Chinese
2019年第四次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2019 Fourth Extraordinary General Meeting of Shareholders" of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and two specific proposals related to the use of idle funds and temporarily idle raised funds for investment and cash management. The content is focused on the meeting organization, shareholder voting rights, and detailed explanations of the proposals to be voted on. There are no financial statements or comprehensive financial data presented, nor is this a transcript of a call or a report publication announcement. The document is clearly the meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length (7603 characters) and content confirm it is the meeting materials, not just an announcement or a brief notice. Therefore, the correct classification is AGM Information (AGM-R).
2019-12-01 Chinese
关于回购注销2017年限制性股票激励计划部分限制性股票的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Corporation regarding the repurchase and cancellation of restricted shares under the 2017 restricted stock incentive plan. It details the number of shares repurchased, the price, the approval process, and the impact on share capital structure. The document is a formal public announcement about a share repurchase related to an employee stock incentive plan, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the share repurchase and cancellation event. Therefore, it fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2019-11-25 Chinese
关于子公司昆药集团医药商业有限公司在云南省临沧市合资新设子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group regarding the establishment of a new joint venture subsidiary. It details the investment amount, the parties involved, the business scope, shareholding structure, and risk factors. The document is relatively short (2253 characters) and focuses on the announcement of a new investment and subsidiary formation. It does not contain financial statements, audit information, or detailed financial performance data. It is not a report but an announcement of a corporate action related to capital investment and subsidiary formation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-11-20 Chinese
九届十六次董事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 9th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various company matters such as acquisitions, capital increases, and investment plans. The document includes the number of votes for, against, and abstentions, and references other related announcements. It is not a full report but an official announcement of board decisions and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, not a full report or presentation.
2019-11-20 Chinese
昆药集团医药商业有限公司拟增资扩股涉及云南昆康企业管理有限公司100%股权价值资产评估报告
Regulatory Filings
2019-11-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.